CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Nov. 6, 2023--
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details for the fireside chats are as follows:
Stifel 2023 Healthcare Conference
Date: Tuesday, November 14, 2023
Time: 8:35 a.m. Eastern Time
Location: New York, NY
Piper Sandler 35th Annual Healthcare Conference
Date: Tuesday, November 28, 2023
Time: 10:30 a.m. Eastern Time
Location: New York, NY
A live webcast of the fireside chats can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for at least 30 days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; RP-3467, a preclinical Polθ inhibitor program; as well as several additional, undisclosed preclinical programs, including RP-1664. For more information, please visit reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231106081922/en/
Repare Contact:
Steve Forte
Executive Vice-President and Chief Financial Officer
Repare Therapeutics Inc.
[email protected]
Investors:
Matthew DeYoung
Argot Partners
[email protected]
Media:
David Rosen
Argot Partners
[email protected]
212-600-1902
Source: Repare Therapeutics Inc.
